The effect of functional status impairment on nursing home admission risk among patients with advanced Parkinson’s disease

References

• Administration for Community Living. Administration on Aging (AoA): Aging statistics Washington, DC: U.S. Department of Health and Human Services; 2016 [cited 2016 Oct 9]. Available from: http://www.aoa.acl.gov/Aging_Statistics/index.aspx.
   Google Scholar
• Congressional Budget Office. Rising demand for long-term services and supports for elderly people. Washington, DC: Congressional Budget Office; 2013. [cited 2015 Dec 11]. Available from: https://www.cbo.gov/sites/default/files/113th-congress-2013-2014/reports/44363-LTC.pdf
   Google Scholar
• KFF.org. Distribution of fee-for-service Medicaid spending on long-term care Menlo Park, CA: The Henry J. Kaiser Foundation; 2016. [cited 2016 Aug 8]. Available from: http://kff.org/medicaid/state-indicator/spending-on-long-term-care/
   Google Scholar
• KFF.org. Total Medicaid spending Menlo Park, CA: The Henry J. Kaiser Family Foundation; 2016 [cited 2016 Aug 8]. Available from: http://kff.org/medicaid/state-indicator/total-medicaid-spending/
   Google Scholar
• Vossius C, Nilsen OB, Larsen JP. Parkinson’s disease and nursing home placement: the economic impact of the need for care. Eur J Neurol. 2009;16(2):194–200.
   PubMed Web of Science ®Google Scholar
• Miller EA, Rosenheck RA. Risk of nursing home admission in association with mental illness nationally in the Department of Veterans Affairs. Med Care. 2006;44(4):343–351.
   PubMed Web of Science ®Google Scholar
• National Institute of Neurological Disorders and Stroke. Parkinson’s disease: challenges, progress, and promise. Bethesda, MD: National Institute of Neurological Disorder and Stroke, National Institutes of Health; 2015 [cited 2016 July 1]. Available from: http://www.ninds.nih.gov/disorders/parkinsons_disease/parkinsons_research.htm.
   Google Scholar
• Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 [meta-analysis]. Neurology. 2007;68(5):384–386.
   PubMed Web of Science ®Google Scholar
• Parkinson’s Disease Foundation. What is Parkinson’s disease? Miami, FL: Parkinson’s Foundation; 2016 [cited 2016 Oct 9]. Available from: http://www.pdf.org/about_pd
   Google Scholar
• Varanese S, Birnbaum Z, Rossi R, et al. Treatment of advanced Parkinson’s disease. Parkinsons Dis. 2010. 480260.
   Web of Science ®Google Scholar
• Fong JH, Mitchell OS, Koh BS. Disaggregating activities of daily living limitations for predicting nursing home admission [Research Support, Non-U S Gov’t]. Health Serv Res. 2015;50(2):560–578.
   PubMed Web of Science ®Google Scholar
• Gaugler JE, Duval S, Anderson KA, et al. Predicting nursing home admission in the U.S: a meta-analysis. BMC Geriatr. 2007;7(1):13.
   PubMedGoogle Scholar
• Olanow CW, Kieburtz K, Odin P, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–149.
   PubMed Web of Science ®Google Scholar
• AbbVie Inc. DUOPA (carbidopa and levodopa) enteral suspension. North Chicago (IL): Abbvie Inc.; 2015.
   Google Scholar
• Antonini A, Odin P, Kleinman L, et al. editors. Implementing a Delphi Panel to improve understanding of patient characteristics of advanced Parkinson’s disease. Proceedings of the MDS 19th International Congress of Parkinson’s Disease and Movement Disorders; 2015 Jun 14–18; San Diego, CA. Hoboken (NJ): Wiley-Blackwell.
   Google Scholar
• Wooldridge JM. Introductory econometrics: a modern approach. Scarborough (ON): Nelson Education; 2015.
   Google Scholar
• Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified Parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–2170.
   PubMed Web of Science ®Google Scholar
• Stuart EA, Bradshaw CP, Leaf PJ. Assessing the generalizability of randomized trial results to target populations. Prev Sci. 2015;16(3):475–485.
   PubMed Web of Science ®Google Scholar
• Clark LT, Watkins L, Piña IL, et al. Increasing diversity in clinical trials: overcoming critical barriers. Curr Probl Cardiol. 2019;44(5):148–172.
   PubMedGoogle Scholar
• Guo J, Konetzka RT, Manning WG. The causal effects of home care use on institutional long-term care utilization and expenditures. Health Econ. 2015;1:4–17.
   Google Scholar
• Kane RA, Kling KC, Bershadsky B, et al. Quality of life measures for nursing home residents. J Gerontol A Biol Sci Med Sci. 2003;58(3):M240–8.
   PubMed Web of Science ®Google Scholar
• Kane RA. Definition, measurement, and correlates of quality of life in nursing homes: toward a reasonable practice, research, and policy agenda. Gerontologist. 2003;43(Supplement 2):28–36.
   PubMed Web of Science ®Google Scholar
• Kaltenboeck A, Johnson SJ, Davis MR, et al. Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease. Parkinsonism Relat Disord. 2012;18(4):321–326.
   PubMed Web of Science ®Google Scholar
• Kowal SL, Dall TM, Chakrabarti R, et al. The current and projected economic burden of Parkinson’s disease in the United States [Research Support, Non-U S Gov’t]. Mov Disord. 2013;28(3):311–318.
   PubMed Web of Science ®Google Scholar
• Antonini A, Yegin A, Preda C, et al. Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients; 12-month interim outcomes. Parkinsonism Relat Disord. 2015;21(3):231–235.
   PubMed Web of Science ®Google Scholar
• Slevin JT, Fernandez HH, Zadikoff C, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinson’s Dis. 2015;5(1):165–174.
   PubMedGoogle Scholar
• Palhagen SE, Sydow O, Johansson A, et al. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson’s disease: an open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism Relat Disord. 2016;29:17–23.
   PubMed Web of Science ®Google Scholar
• Johnson S, Kaltenboeck A, Diener M, et al. Costs of Parkinson’s disease in a privately insured population. Pharmacoeconomics. 2013;31(9):799–806.
   PubMed Web of Science ®Google Scholar
• Saliba D, Orlando M, Wenger NS, et al. Identifying a short functional disability screen for older persons. J Gerontol A Biol Sci Med Sci. 2000;55(12):M750–6.
   PubMed Web of Science ®Google Scholar
• Jekel K, Damian M, Wattmo C, et al. Mild cognitive impairment and deficits in instrumental activities of daily living: a systematic review. Alzheimers Res Ther. 2015;7(1):015–0099.
   PubMedGoogle Scholar
• Bangen KJ, Jak AJ, Schiehser DM, et al. Complex activities of daily living vary by mild cognitive impairment subtype. J Int Neuropsychol Soc. 2010;16(4):630–639.
   PubMed Web of Science ®Google Scholar
• Gaugler JE, Yu F, Krichbaum K, et al. Predictors of nursing home admission for persons with dementia. Med Care. 2009;47(2):191–198.
   PubMed Web of Science ®Google Scholar
• Miller EA, Schneider LS, Rosenheck RA. Predictors of nursing home admission among Alzheimer’s disease patients with psychosis and/or agitation. Int Psychogeriatr. 2011;23(1):44–53.
   PubMed Web of Science ®Google Scholar
• Shih TM, Sullivan J, Sail KR, et al., editors. The effect of functional status on nursing home admission among patients with advanced Parkinson’s disease. Proceedings of the AAN Annual Meeting; 2016 Apr 15–21; Vancouver, BC, Canada: Neurology.
   Google Scholar